Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor

• Published in: Journal of clinical medicine 2022-02, Vol.11 (4), p.1124
• Main Authors: Adamski, Piotr, Barańska, Malwina, Ostrowska, Małgorzata, Kuliczkowski, Wiktor, Buszko, Katarzyna, Kościelska-Kasprzak, Katarzyna, Karolko, Bożena, Mysiak, Andrzej, Kubica, Jacek
• Format: Article
• Language: English
• Subjects: Acute coronary syndromes; Binding sites; Blood platelets; Cardiology; Clinical medicine; Drug dosages; Heart attacks; Ischemia; Kopernik, Mikolaj (Nicolaus Copernicus) (1473-1543); Mortality; Patients; Pharmacodynamics; Thrombosis
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11041124

Contemporary antiplatelet treatment in acute myocardial infarction (AMI) is based on one of two P2Y12 receptor inhibitors, prasugrel or ticagrelor. The aim of this study was to compare diurnal variability of platelet reactivity between patients receiving prasugrel and ticagrelor during the initial phase of maintenance treatment after AMI. It was a prospective, two-center, pharmacodynamic, observational study. Blood for platelet testing was sampled at four time points on day four after AMI (8:00, 12:00, 16:00, 20:00). Diurnal variability of platelet reactivity was expressed as a coefficient of variation (CV) of the above-mentioned measurements. 73 invasively-treated patients were enrolled (ticagrelor: = 47, prasugrel: = 26). CV was greater in patients treated with ticagrelor compared with prasugrel according to a VASP assay (47.8 [31.6-64.6]% vs. 21.3 [12.9-25.5]%, < 0.001), while no statistical differences were detected when the CVs of platelet aggregation according to Multiplate were compared between ticagrelor- and prasugrel-treated patients. Ticagrelor-treated patients showed more pronounced platelet inhibition than prasugrel at 16:00 and 20:00 (VASP : 20.6 ± 15.0 vs. 24.9 ± 12.8 PRI, = 0.049; VASP : 18.6 ± 17.7 vs. 26.0 ± 11.7 PRI, = 0.002). Ticagrelor shows greater diurnal variability in platelet aggregation than prasugrel during the initial maintenance phase of AMI treatment, and this is due to the continuous increase of platelet inhibition after the morning maintenance dose. Both drugs provide an adequate antiplatelet effect early after AMI. Evaluation of the clinical significance of these findings warrants further investigation.